For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
- 17 Companies to List Actos Generics in June, 9 to Delay Listing
June 6, 2011
- Nippon Shinyaku: Sales Up 0.9% to ¥63.5 Bil. Driven by Cialis, Lunabell
June 6, 2011
- Some GE Houses to Delay Listing Actos Generics for 1 Year
June 6, 2011
- Sales Up 33.1% Driven by CMO Business: CMIC
June 6, 2011
- Sawai to Launch Actos Generics with Full Indications in June
June 6, 2011
- Cervarix Ranked No. 1 in GP Market in March: RepTrack Survey
June 6, 2011
- Towa Ready to Launch Generic Actos with Full Indications
June 6, 2011
- Daiichi Sankyo, AZ to Copromote Denosumab in Japan
June 6, 2011
- Toyota Tsusho to Represent GHL in Japan for Biosimilars Contract Manufacturing Service
June 6, 2011
- Wholesalers Were the Only Losers: Chairman Matsutani of Toho
June 6, 2011
- Eisai, UCL to Collaborate in Neurodegenerative Disease
June 6, 2011
- ASKA Licenses Ulipristal from Laboratoire HRA
June 6, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…